share_log

Shareholder Alert: Ademi LLP Investigates Whether Cyclo Therapeutics, Inc. Has Obtained a Fair Price for Its Public Shareholders

Shareholder Alert: Ademi LLP Investigates Whether Cyclo Therapeutics, Inc. Has Obtained a Fair Price for Its Public Shareholders

股東警報:Ademi LLP正在調查Cyclo Therapeutics, Inc.是否爲其公衆股東獲得了公平價格
PR Newswire ·  08/23 13:05

MILWAUKEE, Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Cyclo Therapeutics (Nasdaq: CYTH) for possible breaches of fiduciary duty and other violations of law in its transaction with Rafael Holdings.

Ademi LLP正在調查Cyclo Therapeutics(納斯達克:CYTH),以確定可能存在的違反受託責任和其他法律的行爲。

Click here to learn how to join our investigation or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

點擊這裏了解如何加入我們的調查或撥打Guri Ademi的免費電話:866-264-3995。您不需要承擔任何費用或義務。

Cyclo Therapeutics stockholders will receive only a certain number of shares of Class B common stock of Rafael Holdings, based on an exchange ratio valuing Cyclo Therapeutics shares at $.95 per share and Rafael Holdings at its cash value combined with the value of its marketable securities and certain other investments less certain current liabilities. The transaction agreement unreasonably limits competing transactions for Cyclo Therapeutics by imposing a significant penalty if Cyclo Therapeutics accepts a competing bid. Cyclo Therapeutics insiders will receive substantial benefits as part of change of control arrangements.

Cyclo Therapeutics股東將僅根據交易比率接收一定數量的Rafael Holdings乙類普通股,該比率以每股Cyclo Therapeutics股票價值$0.95和Rafael Holdings的現金價值及其市場證券及某些其他投資價值與某些當前負債相結合。如果Cyclo Therapeutics接受競標,交易協議將不合理地限制Cyclo Therapeutics的競爭交易,同時強加重大懲罰。作爲控制權變更安排的一部分,Cyclo Therapeutics內部人員將獲得實質性利益。

We are investigating the conduct of Cyclo Therapeutics' board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

我們正在調查Cyclo Therapeutics的董事會的行爲,以及他們是否履行對所有股東的受託責任。

If you own Cyclo Therapeutics common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or .

如果您持有Cyclo Therapeutics普通股,並希望獲取額外信息,請聯繫Guri Ademi,郵箱:[email protected],免費電話:866-264-3995,或。

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

我們專門從事全國範圍內有關收購、合併和個人股東權利的股東訴訟。欲了解更多信息,請隨時與我們聯繫。律師廣告。之前的業績不保證類似的結果。

Contacts

聯繫方式

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

Ademi LLP
Guri Ademi
免費電話:(866) 264-3995
傳真:(414) 482-8001

SOURCE Ademi LLP

信息來源:Ademi LLP

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論